Actively Recruiting
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
Led by University of Miami · Updated on 2026-03-05
20
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
Sponsors
U
University of Miami
Lead Sponsor
A
AbbVie
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
CONDITIONS
Official Title
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eye with open-angle glaucoma or suspected of open-angle glaucoma
- Pseudophakic in eye of interest with Shafer grading 653
- Use of 3 or fewer daily topical glaucoma medications for at least 6 months, including one nightly preserved prostaglandin analog
- Good adherence to medication regimen with missing less than or equal to 20% of doses in last month
- Last medication dose administered within 24 hours
- Presence of punctate epithelial erosions in the cornea with NEI scale greater than 3
You will not qualify if you...
- Retinal diseases such as wet age-related macular degeneration, proliferative diabetic retinopathy, or central retinal vein occlusion
- Use of topical or systemic immunosuppressor or immunomodulator drugs like steroids, cyclosporine, lifitegrast, or antihistamines
- Use of preservative-free hypotensive medications
- Any clinical contraindications to intracameral bimatoprost implantation
- History of recurrent conjunctivitis including allergic or atopic conjunctivitis
- History of partial or full corneal transplant
- Ophthalmic surgery involving intraocular or eyelid procedures within last 6 months
- Subconjunctival glaucoma surgery such as trabeculectomy, aqueous shunt, or Xen implant within last 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bascom Palmer Eye Institute
Miami, Florida, United States, 33134
Actively Recruiting
Research Team
J
Javier Paredes, BA, MBA
CONTACT
M
Monica Arango, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here